PA
NVCR icon

Profund Advisors’s NovoCure NVCR Stock Holding History

Profund Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,088
Closed -$241K – 1415
2021
Q2 		$241K Buy
+1,088
New +$212K 0.01% 1233
2020
Q1 		– Sell
-2,635
Closed -$222K – 1039
2019
Q4 		$222K Buy
+2,635
New +$213K 0.01% 1113

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Profund Advisors's NVCR Position: Q3 2021 in Review

Profund Advisors sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 1,088 shares — an estimated $241K sold.

Profund Advisors first reported a position in NVCR in Q4 2019 and held it in 2 quarters. The position peaked at $241K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Profund Advisors reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Profund Advisors sold 1,088 NovoCure shares in Q3 2021, an estimated $241K.
  • Profund Advisors first reported a position in NovoCure in Q4 2019 and held it in 2 quarters.
  • Profund Advisors's NovoCure position peaked at $241K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Profund Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.